MEDIPOST Co., Ltd. (KOSDAQ:078160)

Market Cap	319.16B
Revenue (ttm)	69.86B
Net Income (ttm)	-10.82B
Shares Out	34.10M
EPS (ttm)	-332.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260,481
Average Volume	203,461
Open	9,170.00
Previous Close	9,170.00
Day's Range	9,000.00 - 9,650.00
52-Week Range	5,450.00 - 15,180.00
Beta	0.34
RSI	41.64
Earnings Date	Jan 27, 2025

About MEDIPOST

MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name. The company also offers CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell products, such as PNEUMOSTEM for the preventative treatment of bronchopulmonary dysplasia. Further, the co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 308
• Stock Exchange: KOSDAQ
• Ticker Symbol: 078160

Financial Performance

In 2023, MEDIPOST's revenue was 68.64 billion, an increase of 6.92% compared to the previous year's 64.20 billion. Earnings were 5.84 billion, an increase of 90.31%.